Annexon, Inc. (ANNX)
$
2.03
+0.06 (2.96%)
Key metrics
Financial statements
Free cash flow per share
-0.9445
Market cap
192 Million
Price to sales ratio
0
Debt to equity
0.1161
Current ratio
7.9936
Income quality
0.8352
Average inventory
0
ROE
-0.5445
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Annexon, Inc., a clinical-stage biopharmaceutical company headquartered in Brisbane, California, specializes in uncovering and developing therapeutic solutions for autoimmune, neurodegenerative, and ophthalmic disorders. The total costs and expenses for the company are $0.00 reflecting its overall spending. With a strategic focus on niche markets, the company achieved a revenue of $0.00 indicating its concentrated approach in specific therapeutic areas. Moreover, the operating income ratio stands at 0.00 illustrating the company's operational profitability margin, while the gross profit ratio is 0.00 which highlights the efficiency of its production and sales operations. The gross profit amounts to $0.00 showcasing the company's robust profitability from its core operations. Among its various product candidates, ANX005, a monoclonal antibody, is undergoing Phase II/III clinical trials targeting Guillain-Barré syndrome, as well as a Phase II trial for warm autoimmune hemolytic anemia, and additional studies for Huntington's disease and amyotrophic lateral sclerosis. The company is also advancing ANX009, currently in a Phase Ib trial for lupus nephritis, and ANX007 in Phase II trials aimed at geographic atrophy. Additional investigational products include ANX105, targeting neurodegenerative conditions, and ANX1502, an oral small molecule for specific autoimmune disorders. As a small-cap player with a market capitalization of $222,719,420.00 Annexon is a significant entity in the Biotechnology industry, contributing meaningfully to the overall market landscape. The stock is affordable at $2.03 making it suitable for budget-conscious investors. Furthermore, the stock has a high average trading volume of 1,726,621.00 indicating strong liquidity, which is essential for investors seeking actively traded shares. As a member of the Healthcare sector, Annexon is driving innovation and growth in its field, demonstrating its commitment to enhancing the treatment landscape for patients with challenging medical conditions.
Is Annexon, Inc. (ANNX) a good investment?
Investing in Annexon, Inc. (ANNX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Annexon, Inc. (ANNX)'s stock forecast?
Analysts predict Annexon, Inc. stock to fluctuate between $1.29 (low) and $7.85 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Annexon, Inc.'s market capitalization?
As of 2025-05-29, Annexon, Inc.'s market cap is $222,719,420, based on 109,714,000 outstanding shares.
How does Annexon, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Annexon, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Annexon, Inc. (ANNX) stock?
To buy Annexon, Inc. (ANNX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ANNX. Place an order (Market, Limit, etc.).
What is the best time to invest in Annexon, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Annexon, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.01 | Growth: -42.94%.
Where can I find Annexon, Inc.'s investor relations reports?
Visit https://www.annexonbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Annexon, Inc.?
You can explore historical data from here
What is the all-time high and low for Annexon, Inc. stock?
All-time high: $38.01 (2021-02-22) | All-time low: $1.29 (2025-04-10).
What are the key trends affecting Annexon, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
8 hours ago
BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:10 a.m. EST.
globenewswire.com
10 days ago
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations
globenewswire.com
13 days ago
BRISBANE, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 14, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
18 days ago
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission
globenewswire.com
20 days ago
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compared to Current Standards of Care in Matched Patient Populations
globenewswire.com
23 days ago
Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial Enrolling Globally BRISBANE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced presentations on the neuroprotective effect of ANX007, including consistent benefits of C1q inhibition against inflammation and neuronal damage across diseases.
globenewswire.com
a month ago
BRISBANE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on April 11, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
seekingalpha.com
a month ago
Annexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting with the FDA in H1 2025. The company has $312 million in cash, enough to fund operations into H2 2026, reducing the need for imminent fundraising. Annexon is also developing ANX007 for Geographic Atrophy, with key milestones including enrollment completion in H2 2025 and topline data in H2 2026.
globenewswire.com
2 months ago
Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS
globenewswire.com
2 months ago
Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points
See all news
